Cargando…
FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
BACKGROUND: The Office of Orphan Products Development (OOPD) of the United States (U.S.) Food and Drug Administration (FDA) has awarded over 700 grants to conduct clinical trials of medicals products for rare diseases since 1983, leading to over 70 marketing approvals. However, despite recent progre...
Autores principales: | Miller, Kathleen L., Mueller, Christine, Liu, Gumei, Miller Needleman, Katherine I., Maynard, Janet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469294/ https://www.ncbi.nlm.nih.gov/pubmed/32883327 http://dx.doi.org/10.1186/s13023-020-01514-5 |
Ejemplares similares
-
Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
por: Miller, Kathleen L., et al.
Publicado: (2021) -
Do investors value the FDA orphan drug designation?
por: Miller, Kathleen L.
Publicado: (2017) -
Precision Medicines’ Impact on Orphan Drug Designation
por: Mueller, Christine M., et al.
Publicado: (2019) -
Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012
por: Pauwels, Kim, et al.
Publicado: (2017) -
Investigating the landscape of US orphan product approvals
por: Miller, Kathleen L., et al.
Publicado: (2018)